SALT LAKE CITY, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark
C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2016 Morgan Stanley Global Healthcare Conference at
9:20 a.m. ET on September 12, 2016, at the Grand Hyatt New York in New York City.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor
information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that:
determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression and guide treatment
decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower
healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer
testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue
contribution from international markets. For more information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk
Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or
registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G
Media Contact: Ron Rogers (908) 285-0248 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com
